12-({5-[(3aS,4S,6aR)-2-羰基六氢-1H-噻吩并[3,4-d]咪唑-4-基]戊酰基}氨基)十二烷酸 | 135447-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 中文名称: 12-({5-[(3aS,4S,6aR)-2-羰基六氢-1H-噻吩并[3,4-d]咪唑-4-基]戊酰基}氨基)十二烷酸
• 中文别名: N-生物素基-12-氨基十二烷酸
• 英文名称: N-Biotinyl-12-aminododecanoic Acid
• 英文别名: 12-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]dodecanoic acid
• CAS: 135447-73-3
• 化学式: C₂₂H₃₉N₃O₄S
• 分子量: 441.6
• InChiKey: ALIFRMFPRBTNNH-WFXMLNOXSA-N

物化性质

• 熔点：
  215-217°C
• 溶解度：
  DMF（少量）、DMSO（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  30
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• WGK Germany：
  3

文献信息

• Lipid construct for delivery of insulin to a mammal
  申请人：SDG, INC.

  公开号：US10004686B2

  公开（公告）日：2018-06-26

  The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

  本发明涉及一种肝细胞靶向组合物，该组合物包含与脂质构建物相关联的胰岛素，脂质构建物包括两性脂质和扩展两性脂质，该构建物可靶向肝细胞显示的受体。 该组合物可包括游离胰岛素和与复合物相关的胰岛素的混合物。 可以对组合物进行修饰，以保护胰岛素和复合物不被降解。 本发明还包括制造组合物、将胰岛素装入组合物以及回收组合物中各种成分的方法。 治疗糖尿病患者的方法。
• Orally bioavailable lipid-based constructs
  申请人：SDG, INC.

  公开号：US10568835B2

  公开（公告）日：2020-02-25

  The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

  本发明体现为一种组合物，它能够通过消化道环境对通常非口服的治疗剂或诊断剂进行陪衬，从而使治疗剂或诊断剂具有生物可利用性。该组合物可以针对或不针对特定的细胞受体，如肝细胞。治疗剂包括但不限于胰岛素、降钙素、血清素和其他蛋白质。生物素或金属靶向剂可实现靶向。
• Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
  申请人：SDG, Inc.

  公开号：US10918700B2

  公开（公告）日：2021-02-16

  The invention provides methods of treating a subject having diabetes mellitus and/or a metabolic derangement.

  本发明提供了治疗糖尿病和/或代谢紊乱患者的方法。
• Lipid-based nanoparticles and methods using same
  申请人：SDG, Inc.

  公开号：US11071715B2

  公开（公告）日：2021-07-27

  The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.

  本发明提供了一种改进的脂基纳米粒子，可用于向受试者（如但不限于哺乳动物，如但不限于人类）递送治疗剂。在某些实施方案中，与现有技术中的纳米粒子相比，本发明的纳米粒子具有更低的聚集特性。
• Method of detection of influenza virus and compounds for use therein
  申请人：——

  公开号：US20020055094A1

  公开（公告）日：2002-05-09

  The invention provides a method of detection of influenza virus which utilises compounds able to bind specifically to the active site of influenza virus neuraminidase, and novel compounds for use in the method.

  本发明提供了一种利用能与流感病毒神经氨酸酶活性位点特异性结合的化合物检测流感病毒的方法，以及用于该方法的新型化合物。